Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

ATP sensitive potassium (KATP) channel inhibition: A promising new drug target for migraine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Googling migraine: A study of Google as an information resource of migraine management

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Habitual sleep disturbances and migraine: a Mendelian randomization study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Functional gene networks reveal distinct mechanisms segregating in migraine families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. No central action of CGRP antagonising drugs in the GTN mouse model of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Recently, the adenosine triphosphate (ATP) sensitive potassium channel opener levcromakalim was shown to induce migraine attacks with a far higher incidence than any previous provoking agent such as calcitonin gene-related peptide. Here, we show efficacy of ATP sensitive potassium channel inhibitors in two validated rodent models of migraine.

METHODS: In female spontaneous trigeminal allodynic rats, the sensitivity of the frontal region of the head was tested by an electronic von Frey filament device. In mice, cutaneous hypersensitivity was induced by repeated glyceryl trinitrate or levcromakalim injections over nine days, as measured with von Frey filaments in the hindpaw. Release of calcitonin gene-related peptide from dura mater and trigeminal ganglion was studied ex vivo.

RESULTS: The ATP sensitive potassium channel inhibitor glibenclamide attenuated the spontaneous cephalic hypersensitivity in spontaneous trigeminal allodynic rats and glyceryl trinitrate-induced hypersensitivity of the hindpaw in mice. It also inhibited CGRP release from dura mater and the trigeminal ganglion isolated from spontaneous trigeminal allodynic rats. The hypersensitivity was also diminished by the structurally different ATP sensitive potassium channel inhibitor gliquidone. Mice injected with the ATP sensitive potassium channel opener levcromakalim developed a progressive hypersensitivity that was completely blocked by glibenclamide, confirming target engagement.

CONCLUSION: The results suggest that ATP sensitive potassium channel inhibitors could be novel and highly effective drugs in the treatment of migraine.

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind40
Udgave nummer7
Sider (fra-til)650-664
Antal sider15
ISSN0333-1024
DOI
StatusUdgivet - 2020

ID: 60054569